Logo image of MOLN

MOLECULAR PARTNERS AG -ADR (MOLN) Stock Fundamental Analysis

NASDAQ:MOLN - Nasdaq - US60853G1067 - ADR - Currency: USD

3.76  -0.08 (-2.08%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to MOLN. MOLN was compared to 557 industry peers in the Biotechnology industry. The financial health of MOLN is average, but there are quite some concerns on its profitability. MOLN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

MOLN had negative earnings in the past year.
MOLN had a negative operating cash flow in the past year.
In the past 5 years MOLN reported 4 times negative net income.
MOLN had negative operating cash flow in 4 of the past 5 years.
MOLN Yearly Net Income VS EBIT VS OCF VS FCFMOLN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

1.2 Ratios

With a decent Return On Assets value of -34.09%, MOLN is doing good in the industry, outperforming 62.48% of the companies in the same industry.
MOLN has a Return On Equity of -38.16%. This is in the better half of the industry: MOLN outperforms 71.81% of its industry peers.
Industry RankSector Rank
ROA -34.09%
ROE -38.16%
ROIC N/A
ROA(3y)-6.8%
ROA(5y)-18.16%
ROE(3y)-7.72%
ROE(5y)-28.23%
ROIC(3y)N/A
ROIC(5y)N/A
MOLN Yearly ROA, ROE, ROICMOLN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

1.3 Margins

MOLN has a Gross Margin of 99.80%. This is amongst the best in the industry. MOLN outperforms 99.28% of its industry peers.
MOLN's Gross Margin has been stable in the last couple of years.
MOLN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.14%
GM growth 5Y0.01%
MOLN Yearly Profit, Operating, Gross MarginsMOLN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

5

2. Health

2.1 Basic Checks

MOLN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MOLN has more shares outstanding
MOLN has more shares outstanding than it did 5 years ago.
The debt/assets ratio for MOLN has been reduced compared to a year ago.
MOLN Yearly Shares OutstandingMOLN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
MOLN Yearly Total Debt VS Total AssetsMOLN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of 1.67, we must say that MOLN is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of MOLN (1.67) is better than 69.48% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that MOLN is not too dependend on debt financing.
MOLN's Debt to Equity ratio of 0.01 is in line compared to the rest of the industry. MOLN outperforms 42.19% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 1.67
ROIC/WACCN/A
WACC4.87%
MOLN Yearly LT Debt VS Equity VS FCFMOLN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

MOLN has a Current Ratio of 14.31. This indicates that MOLN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 14.31, MOLN belongs to the top of the industry, outperforming 86.36% of the companies in the same industry.
MOLN has a Quick Ratio of 14.31. This indicates that MOLN is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of MOLN (14.31) is better than 86.36% of its industry peers.
Industry RankSector Rank
Current Ratio 14.31
Quick Ratio 14.31
MOLN Yearly Current Assets VS Current LiabilitesMOLN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

MOLN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.75%, which is quite impressive.
Looking at the last year, MOLN shows a very negative growth in Revenue. The Revenue has decreased by -60.65% in the last year.
Measured over the past years, MOLN shows a very negative growth in Revenue. The Revenue has been decreasing by -24.59% on average per year.
EPS 1Y (TTM)40.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%49.96%
Revenue 1Y (TTM)-60.65%
Revenue growth 3Y-20.13%
Revenue growth 5Y-24.59%
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, MOLN will show a decrease in Earnings Per Share. The EPS will decrease by -2.42% on average per year.
The Revenue is expected to grow by 94.34% on average over the next years. This is a very strong growth
EPS Next Y7.01%
EPS Next 2Y5.2%
EPS Next 3Y15.32%
EPS Next 5Y-2.42%
Revenue Next Year-75%
Revenue Next 2Y55.46%
Revenue Next 3Y104.08%
Revenue Next 5Y94.34%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MOLN Yearly Revenue VS EstimatesMOLN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
MOLN Yearly EPS VS EstimatesMOLN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MOLN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MOLN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MOLN Price Earnings VS Forward Price EarningsMOLN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MOLN Per share dataMOLN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

MOLN's earnings are expected to grow with 15.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.2%
EPS Next 3Y15.32%

More info and screens

0

5. Dividend

5.1 Amount

MOLN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MOLECULAR PARTNERS AG -ADR

NASDAQ:MOLN (6/17/2025, 8:00:01 PM)

3.76

-0.08 (-2.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-06 2025-03-06/amc
Earnings (Next)08-25 2025-08-25
Inst Owners45.02%
Inst Owner Change-0.01%
Ins Owners4%
Ins Owner ChangeN/A
Market Cap138.65M
Analysts82.22
Price Target12.76 (239.36%)
Short Float %0.13%
Short Ratio3.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.77%
PT rev (3m)-0.52%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)17.84%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-57.14%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 22.68
P/FCF N/A
P/OCF N/A
P/B 0.8
P/tB 0.8
EV/EBITDA N/A
EPS(TTM)-1.96
EYN/A
EPS(NY)-1.91
Fwd EYN/A
FCF(TTM)-2
FCFYN/A
OCF(TTM)-1.98
OCFYN/A
SpS0.17
BVpS4.72
TBVpS4.72
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.09%
ROE -38.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.8%
FCFM N/A
ROA(3y)-6.8%
ROA(5y)-18.16%
ROE(3y)-7.72%
ROE(5y)-28.23%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.14%
GM growth 5Y0.01%
F-Score4
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.52%
Cap/Sales 14.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.31
Quick Ratio 14.31
Altman-Z 1.67
F-Score4
WACC4.87%
ROIC/WACCN/A
Cap/Depr(3y)41.08%
Cap/Depr(5y)46.5%
Cap/Sales(3y)8.93%
Cap/Sales(5y)11.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%49.96%
EPS Next Y7.01%
EPS Next 2Y5.2%
EPS Next 3Y15.32%
EPS Next 5Y-2.42%
Revenue 1Y (TTM)-60.65%
Revenue growth 3Y-20.13%
Revenue growth 5Y-24.59%
Sales Q2Q%-100%
Revenue Next Year-75%
Revenue Next 2Y55.46%
Revenue Next 3Y104.08%
Revenue Next 5Y94.34%
EBIT growth 1Y31.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.56%
EBIT Next 3Y20.63%
EBIT Next 5YN/A
FCF growth 1Y-0.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-0.41%
OCF growth 3YN/A
OCF growth 5YN/A